POL1 Inhibitor Crystal Forms for Handling, Stability, and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing crystalline forms of N-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzo[4,5]imidazo[1,2-a][1,8]naphthyridine-6-carbaxomide exhibit poor handling characteristics, high aggregation tendencies, and instability, which complicates their use in solid dosage forms and affects solubility and stability.
Innovation Solution
Development of specific crystalline forms (Forms 1-5) with improved handling, stability, and solubility profiles, characterized by distinct X-ray diffraction patterns and thermal properties, achieved through controlled crystallization processes using various solvents and temperature cycling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If existing crystalline forms of Compound (I) are used, then the compound can be obtained, but handling characteristics are poor and aggregation tendency is high
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing five distinct crystalline forms (Forms 1-5) of Compound (I), each with unique physical properties including different X-ray diffraction patterns, melting points, and solubility characteristics. This transformation from a single undefined crystalline form to multiple characterized forms with optimized parameters directly resolves the handling and aggregation issues.
2Reliability
If existing crystalline forms of Compound (I) are used, then the compound can be obtained, but stability is poor
Solution Approach 1:
The patent resolves stability issues by characterizing five distinct crystalline forms with different thermal and physical stability profiles. Each form exhibits unique stability characteristics under various conditions, allowing selection of the most stable form for long-term storage and handling. The differential scanning calorimetry and thermogravimetric analysis data provide evidence of enhanced stability for specific forms.
3Quantity of substance
If existing crystalline forms of Compound (I) are used, then the compound can be obtained, but solubility is poor
Solution Approach 1:
The patent addresses solubility issues by characterizing five crystalline forms with distinct solubility profiles in various solvents. The patent provides solubility data showing that different forms exhibit varying degrees of solubility, enabling selection of the optimal form for achieving consistent and reliable solubility characteristics in pharmaceutical formulations.
4Productivity
If existing crystalline forms of Compound (I) are used, then the compound can be obtained, but consistency in solid dosage form production is poor
Solution Approach 1:
The patent resolves production consistency issues by providing detailed characterization of five crystalline forms including their X-ray diffraction patterns, melting points, and other physical properties. This level of characterization enables quality control and ensures that the selected crystalline form can be consistently manufactured and processed into uniform solid dosage forms with predictable performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystalline forms provide enhanced handling, stability, and solubility, facilitating consistent production of solid dosage forms and improving therapeutic efficacy in treating conditions like cancer and inflammation.
Implementation Method 1
characterized by distinct X-ray diffraction patterns
Implementation Method 2
distinct X-ray diffraction patterns and thermal properties
Data Source
AI summary
The present invention relates to novel solid crystalline form of N-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzo[4,5]imidazo[1,2-a][1,8]naphthyridine-6-carbaxomide, processes for the preparation thereof, compositions thereof and method of use thereof.